Objective    To study the feasibility of irinotecan plus cisplatin and image-guided radiotherapy in treatment of advanced non-small cell lung cancer (NSCLC).     Methods    Twelve patients with locally advanced NSCLC and a performance status of 0 or 1 were eligible. The protocol consisted of escalating doses of irinotecan on days 1

8 and 15

and cisplatin (75 mg/m

2

administered equal split doses on days 1-3) for a total of 2 to 3 cycles combined with concurrent kV-CBCT guided 3D conformal radiotherapy (2.0 Gy daily for a total dose of 66 Gy).     Results    The maximum tolerable dose o

f irinotecan was 60 mg/m

2

and the dose-limiting toxicity was neutropenia and esophagitis. Tumor response was observed in 75% cases. The median survival time of the 12 patients enrolled was 11.5 months

and no symptomatic pneumonitis or esophagitis presented.     Conclusion    Accompanied by conformal therapy

the tolerated dose that irinotecan at 60 mg/m

2

on days 1

8

15

and cisplatin at 75 mg/m

2

is recommended for phase Ⅱ trial.